Introduction
BPH is characterized by smooth muscle and epithelial cell proliferation within the prostatic transition zone, 1 and causes bothersome LUTS, comprising voiding, storage and post-micturition symptoms that affect QoL by interfering with daily activities and sleep. 2, 3 Epidemiological studies confirm that LUTS-BPH is common and increases with age, with an overall prevalence of approximately 25% in men aged ≥50 years. 4, 5 The main goal of LUTS-BPH management is to relieve LUTS and thereby improve QoL. 6 Treatments recommended for LUTS-BPH by guidelines include a-blockers (e.g. tamsulosin, silodosin) and 5a-reductase inhibitors (dutasteride and finasteride). 1, 6, 7 These treatments can be effective, but might have adverse effects, including sexual dysfunction (a-blockers/5a-reductase inhibitor), orthostatic hypotension (a-blockers) and intraoperative floppy iris syndrome during cataract surgery (a-blockers). 1, 6, 7 Approval of the long-acting phosphodiesterase type 5 inhibitor tadalafil 5 mg once daily increased LUTS-BPH treatment options in a number of countries. Trials have shown that the mean change from baseline to end-point in the total IPSS (primary endpoint) is significantly greater in patients treated with tadalafil than patients treated with a placebo. [8] [9] [10] [11] Data from these trials showed that tadalafil was not related to certain sexual dysfunction side-effects previously reported with other BPH treatments. [8] [9] [10] [11] Physicians who treat LUTS-BPH are required to understand individual patient needs, set appropriate treatment goals and, ideally, predict treatment response. However, information on predicting treatment response at an early stage is limited. Although various questionnaires are used to assess disease condition and QoL in patients with LUTS-BPH, IPSS is most commonly used in clinical settings. 12 Research suggests that a greater total IPSS is strongly correlated with reduced QoL. 13 Existing studies have shown an association between IPSS and QoL at baseline. Stronger scientific arguments could come from analysis of similar relationships after treatment, but very limited data on this are available. 14, 15 Further, the association between treatment outcomes and the changes in individual IPSS scores at an early stage has not been fully explored.
The aims of the present study were to analyze whether early changes in individual IPSS scores could predict final improvement in a patient's QoL or satisfaction when treated with tadalafil. Further, the present study sought to establish if any pattern in such changes in individual IPSS scores contributed to the treatment outcomes.
Methods

Data sources
The present post-hoc analysis was based on three placebocontrolled, randomized, double-blind trials (LVHB, LVJF, LVIA) of tadalafil 2.5 or 5.0 mg daily for the treatment of BPH-LUTS. [16] [17] [18] [19] Individual trials required that patients met inclusion criteria, including age ≥45 years, total IPSS ≥13 at the beginning of treatment and bladder outlet obstruction (indicated by maximum flow rate 4-15 mL/s). Patients were excluded if they had a prostate-specific antigen score >10.0 ng/mL (or ≥4 and ≤10.0 ng/mL if prostate cancer could not be ruled out) at study entry, or a bladder postvoid residual volume ≥300 mL. All participants agreed not to use other treatments for BPH, erectile dysfunction or overactive bladder during the study, including a-blockers, 5-a reductase inhibitors, phosphodiesterase type 5 inhibitors (other than study medication) or herbal preparations. Pooled analysis from these three trials showed improvement in total IPSS, IPSS storage subscore, IPSS voiding subscore, IPSS QoL index and PGI-I. 19 
Time frame of analysis
The analysis time frame was restricted to the early phase (visit 3-visit 6) and last observation (visit 7) of the doubleblind treatment period of the included studies. Visits 3, 4, 5, 6 and 7 corresponded to weeks 0, 2, 4, 8 and 12, after the start of double-blind treatment.
Analysis population
Four distinct analysis subpopulations were defined as below (see Table S1 for analysis population conditions):
Description of instruments
IPSS
The IPSS comprises seven questions ranging from 0 (none/ not at all) to 5 (almost always/5 or more times) regarding urinary storage symptoms (IPSS items 2, 4 and 7) and voiding symptoms (IPSS items 1, 3, 5 and 6) over the previous month (Table S2 ). The IPSS-QoL item was asked at the end of the IPSS questionnaire, but not considered part of the total IPSS. 20 
PGI-I
The PGI-I scale is a single-item subject-rated instrument that measures the improvement or worsening of urinary symptoms at the last visit compared with before taking study medication (Table S3) . 21 Each item comparison is rated from 1 ("very much better") to 7 ("very much worse"). The PGI-I has been validated in men with LUTS-BPH, showing a correlation with changes in IPSS and IPSS-QoL (Spearman's correlation coefficients 0.56 and 0.53, respectively; P < 0.001). 22 
Statistical analysis
Logistic regression
The first approach used to predict the effect of tadalafil on IPSS items was logistic regression analysis, for which three separate logistic models were used at each visit: IPSS remitter, IPSS responder and PGI-I responder. For each logistic regression, final models were selected by backward algorithm. If a particular IPSS item was identified either by the IPSS remitter or responder analysis, it was marked in the first column (1A) of the results summary table. Similarly, if a particular item was identified by the PGI-I responder analysis, it was marked in the second column (1B) of the results summary table.
PCA PCA with a Varimax rotation was determined if the total IPSS and PGI-I at week 12 were associated with improvement in individual IPSS items at each postbaseline visit. As PCA can result in different groupings for different inputs, we used three different datasets (2A, 2B, 2C) to obtain robust results. From the perspective of week 12 data, 2A contains the total IPSS change from baseline and PGI-I, 2B only PGI-I and 2C only the total IPSS change from baseline. A similar method was used in an analysis of placebo-controlled trials of participants with depression to determine if there was a pattern of symptom improvement. 23 
Hierarchical clustering analysis
Within each visit, each item's improvement pattern was investigated using hierarchical clustering analysis, which is a widely used algorithm to build a binary tree. The algorithm can identify if a similar pattern is observed across patients at a visit, and rank items based on their closeness as measured by a certain distance. The scale normalization is defined in Table S3 . Euclidian distance with the centroid method was used.
All statistical analyses were carried out using SAS version 9.2 (SAS Institute, Cary, NC, USA).
Results
The demographic and baseline disease characteristics of enrolled patients from both Asia and Japan have been described in detail previously (LVHB, LVJF, LVIA). [16] [17] [18] [19] Analyzable patient numbers in each study were as follows: LVHB, n = 422 (PLA, n = 145; TAD 2.5 mg, n = 137; TAD 5.0 mg, n = 140); LVJF, n = 586 (PLA, n = 294; TAD 5.0 mg, n = 292); and LVIA, n = 402 (PLA, n = 135; TAD 2.5 mg, n = 137; TAD 5.0 mg, n = 130). Demographic and baseline characteristics were generally balanced between the tadalafil and placebo treatment groups in each trial (LVHB, LVJF, LVIA).
Logistic regression
For the TAD/ASIA, most IPSS items were identified at all visits by the IPSS remitter or responder analysis (1A Table 1, Table S4 ). For example, IPSS items 1, 2, 4, 5, 6, 7 and IPSS QoL were identified at week 2, whereas IPSS QoL was not identified at weeks 4 and 8. In contrast, IPSS QoL was the only item identified by the PGI-I responder analysis at all visits (1B Table 1, Table S4 ). Identified IPSS items for TAD/JPN were generally similar to those for TAD/ASIA. For the PLA/ASIA and PLA/JPN, most IPSS items except IPSS QoL were identified at all visits by the IPSS remitter or responder analysis (1A Table 1, Table S4 ). In contrast to tadalafil-treated patients, IPSS QoL was not always identified by the PGI-I responder analysis in placebo-treated patients (1B Table 1, Table S4 ). In summary, total IPSS (week 12) was associated with IPSS items 1-7 and PGI-I (week 12) with IPSS QoL for the tadalafil-treated patients.
Principal component analysis
The results were summarized in two groups: (i) a group with total IPSS (week 12) change from baseline (columns 2A and 2C, Table 1 ); and (ii) a group with PGI-I (week 12; columns 2A and 2B, Table 1 ). For TAD/ASIA at week 4, IPSS items 1, 3, 5 and 6 were associated with total IPSS by both (2A) and (2C), whereas IPSS items 2, 4 and 7 were associated with PGI-I by both (2A) and (2B). Further, at week 8, IPSS items 1, 3, 5 and 6 were associated with total IPSS by (2A), and IPSS items 2, 4, 7 and IPSS QoL were associated with PGI-I by both (2A) and (2B). Total IPSS and PGI-I grouping results for TAD/JPN were generally similar to those for TAD/ASIA. For PLA/ASIA and PLA/JPN, there was no clear trend at week 2, whereas most IPSS items were associated with both total IPSS and PGI-I at week 4 and week 8. In summary, for the tadalafil-treated patients, IPSS items 1, 3, 5 and 6 were associated with total IPSS (week 12), and IPSS items 2, 4, 7 and IPSS QoL were associated with PGI-I (week 12). Comprehensive results of the PCA are shown in Table S5 .
Hierarchical clustering analysis
Results of the clustering analysis at each visit showed cluster ordering originated with the IPSS QoL item. The analysis (3) in Table 1 shows the top three IPSS items closest to IPSS QoL at each visit. For TAD/ASIA, IPSS items 1, 4 and 7 were associated with IPSS QoL at weeks 2 and 4, whereas IPSS items 1, 2 and 7 were associated with IPSS QoL at week 8. For TAD/JPN, IPSS items 1, 4 and 7 were associated with IPSS QoL at all visits. For PLA/ASIA and PLA/ JPN, IPSS items 1, 4 and 7 were generally associated with IPSS QoL. The results from the supplemental cluster analysis showed that item 7 was consistently closest to IPSS QoL regardless of the analysis (Table S6) .
Discussion
From logistic regression results, most individual IPSS items predicted either IPSS remitter or responder status, and only IPSS QoL predicted PGI-I responder status in tadalafil-treated patients. These results were not surprising, because their status is a function of total IPSS evaluated at week 12, which was based on IPSS items 1-7, not IPSS QoL. The model did not distinguish items 1-7. Conversely, for the PGI-I responder analysis, IPSS QoL was consistently identified, showing strong evidence of the association. The other IPSS items were not identified in general. Logistic regression has inherent drawbacks, as it transforms end-point variables into binary outputs, which implies loss of original item scores. To make full use of available information, PCA and hierarchical clustering analysis were used.
A previous study that used PCA showed that the IPSS can be divided into a voiding subscore defined as IPSS items 2, 4 and 7, and a storage subscore defined as IPSS items 1, 3, 5 and 6, each comprised of certain items, 24 although this analysis used IPSS at particular visits (static approach). In the present study, we took a new, dynamic approach and applied PCA to improvement in IPSS (i.e. change from baseline in items at particular visits). Further, we merged the end-point values into the analysis (i.e. total IPSS change from baseline at week 12 and PGI-I at week 12). By taking this approach, we can identify improvement in associated items at week 2, 4 or 8 with PGI-I and/or the change of total as prediction factors. The results of the three analyses (2A, 2B, 2C) showed that, for predicting tadalafil treatment outcomes among patients in Asia and Japan, IPSS items 1, 3, 5 and 6 were associated with total IPSS (week 12), and IPSS items 2, 4, 7 and IPSS QoL were associated with PGI-I (week 12). In contrast, for placebo-treated patients, there were no clear predictive items for PGI-I and total IPSS. Finally, it is important to note that all analyses were carried out using individual items, rather than subscores. Therefore, these post-analysis associations represent spontaneous findings rather than confirming the relative contribution of subscore items.
Hierarchical clustering, which provides additional ranking information from constructed binary trees, was applied to IPSS items 1-7 and IPSS QoL at each visit to check the robustness of the PCA. Results showed that the closest association was between IPSS QoL and IPSS item 7, with items 1 and 4 also identified in the top three closest items at most time-points. For tadalafil-treated patients, both the factor and clustering analyses gave similar trends. For placebo-treated patients, PCA gave no specific trend, whereas clustering analysis gave a similar ranking as tadalafil-treated patients. Note that, even though there are only subtle differences among items, the clustering algorithm always gives ranking for all items, whereas PCA might not differentiate items at all. Considering the nature of both methods, we do not see any contradictions in the conclusion reached. Rather, the results of the clustering analysis strengthened those of the PCA in the tadalafil-treated group. Overall, as expected, Asia and Japan showed similar trends, because the Japanese population comprised approximately 70% of the Asian population in these studies.
The present analysis showed that improvement of IPSS storage symptoms (IPSS items 2, 4 and 7) at the early phase of tadalafil treatment might lead to better patient QoL and later improvement in treatment outcomes. We also found that early improvement in voiding symptoms (IPSS items 1, 3, 5 and 6) might contribute more to later improvement in total IPSS.
Tadalafil is thought to improve LUTS through mechanisms including smooth muscle relaxation in the LUT tissue and the vasculature, as well as by modulation of bladder afferent nerve activity. 25 Although tadalafil improved both voiding and storage symptoms in large randomized clinical studies, improvement of voiding symptoms was generally greater than that of storage symptoms. [17] [18] [19] Therefore, the effect of tadalafil on storage symptoms in the present study might elucidate this underappreciated clinical benefit. Development of storage symptoms is attributed to the impairment of bladder function that prevents involuntary bladder emptying. Tadalafil might ameliorate storage dysfunction by decreasing the afferent activity of both Ad-and C-fibers induced by bladder distension. 26 The present results support the view that the improvement of afferent nerve function possible with early tadalafil treatment significantly impacts the clinical outcome of patients with compromised storage function. These results are consistent with previous observations suggesting that addressing storage symptoms is important for improving patient treatment satisfaction. Specifically, the present findings suggest that there is a relationship between an improvement in IPSS storage symptoms at weeks 2, 4 and 8 and PGI-I at week 12, which is consistent with previous research showing that storage symptoms might contribute to reduced QoL to a greater extent than voiding symptoms. 15, 27, 28 Further, our finding of the strongest QoL association with IPSS item 7 (nocturia) is consistent with previous findings that a greater frequency of nocturia contributes to incremental decreases in QoL. 2, 3, 29, 30 Clinically, these results help physicians predict the clinical outcome of LUTS-BPH treatment and also provide options for tailoring the approach to meet individual treatment goals (e.g. primarily removing functional or mechanical obstruction and/or improving patient QoL). Finally, the present results might also promote understanding of the complex pathophysiology of LUTS-BPH and its contribution to the development of clinical symptoms. In patients treated with tadalafil, there seems to be a distinct pattern in IPSS changes that later leads to specific symptom improvement, suggesting that these patterns are caused by different pathophysiological mechanisms behind the disease manifestation.
Although tadalafil improved both voiding and storage symptoms in large clinical trials, our analysis shows that an early change in IPSS score could predict final treatment outcomes. The present analysis also suggests that: (i) PGI-I response can be predicted by early improvement in storage symptoms (IPSS items 2, 4 and 7) and IPSS QoL improvement; (ii) greater frequency of nocturia (IPSS item 7) is associated with decreased QoL; and (iii) improvement of total IPSS can be predicted by early improvement in voiding symptoms (IPSS items 1, 3, 5 and 6). These findings might help clinicians to individualize the treatment of patients with LUTS-BPH, and improve patient's QoL and symptoms by facilitating evidence-based treatment decisions.
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